SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB

The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders. 1000 -o-25 mg IR -- 25 mg SR-1 -+-25 mg SR-2 ac1...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	WILLIAMS, William V, ERICKSON-VIITANEN, Susan, YELESWARAM, Krishnaswamy, NI, Yong, PARIKH, Bhavnish
Format:	Patent
Sprache:	eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders. 1000 -o-25 mg IR -- 25 mg SR-1 -+-25 mg SR-2 ac100 O (D 1 - . . , . . , . . , . . , . . , . 0 6 12 18 24 30 36 Time (h)